Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
Litigation Timeline
Second Circuit Hears Oral Arguments — November 17, 2025
The Second Circuit Court of Appeals heard oral arguments in the appeal of MDL-3043's dismissal on November 17, 2025 in New York. In a development widely reported by legal observers, two of the three judges on the panel openly questioned whether Judge Cote had acted too aggressively in excluding plaintiffs' general causation experts under Daubert. One judge asked whether the case-specific evidence for individual plaintiffs should have been evaluated even if general causation experts were excluded at the MDL level. Legal analysts consider the appellate skepticism of the lower court's ruling to be a meaningful signal, though oral argument questions do not guarantee a particular outcome. A ruling from the Second Circuit is expected in 2026.
litigationCalifornia and Illinois State Court Cases Remain Active
While the federal MDL was dismissed in August 2024, state court litigation in California (Alameda County) and Illinois (St. Clair, Madison, and Cook counties) continues under the Frye admissibility standard. California courts apply the Kelly-Frye test, which asks whether the expert's scientific methodology is generally accepted in the relevant scientific community — a standard more favorable to plaintiffs given the 91-scientist Nature Reviews Endocrinology consensus statement. Illinois courts similarly apply Frye. In October 2025, the Texas Attorney General filed suit against Johnson & Johnson and Kenvue for failure to warn, adding a government-enforcement dimension to the litigation. The HHS Secretary announced in September 2025 that the Department of Health and Human Services had identified prenatal acetaminophen as a contributor to rising autism rates and directed the FDA to evaluate label changes. These regulatory and governmental developments support the general-acceptance argument under Frye.
litigationJudge Cote Dismisses MDL-3043 via Daubert Exclusion
Judge Denise L. Cote issued a sweeping Daubert ruling excluding all of the plaintiffs' general causation expert witnesses in MDL-3043. The court found that plaintiffs' experts had not used sufficiently reliable methodologies to establish that prenatal acetaminophen causes ASD or ADHD — citing concerns about inadequate confounding adjustment, improper extrapolation from animal studies, and methodological inconsistencies. Without admissible general causation experts, plaintiffs could not meet their burden of proof, and the MDL was dismissed. The ruling was a significant setback but applies only to the federal MDL; it does not govern state courts in California, Illinois, or elsewhere.
litigationMDL-3043 Formed in S.D.N.Y.
The Judicial Panel on Multidistrict Litigation consolidated federal acetaminophen-ASD/ADHD cases as MDL-3043 — In re Acetaminophen ASD/ADHD Products Liability Litigation — in the Southern District of New York, assigned to Judge Denise L. Cote. At its peak, MDL-3043 involved hundreds of cases and 14+ defendants including Kenvue (Johnson & Johnson's consumer health spinoff), Walmart, CVS, Walgreens, Rite Aid, Costco, and Meijer. The formation of a federal MDL signaled the scale of the litigation and prompted a wave of additional filings by families nationwide.
litigationNature Reviews Endocrinology Consensus Statement — 91 Scientists
A consensus statement signed by 91 scientists and physicians from 17 countries was published in Nature Reviews Endocrinology, calling for precautionary guidance on the use of acetaminophen during pregnancy. The statement concluded that prenatal exposure to acetaminophen is associated with increased risk of neurodevelopmental disorders including ASD and ADHD, and that healthcare providers should counsel pregnant women to use the lowest effective dose for the shortest possible time. This was the most significant scientific validation of plaintiffs' position to date, and it is central to the Frye-standard litigation in California and Illinois, where the question is whether the methodology is generally accepted — a bar the consensus statement squarely addresses.
scientificJAMA Psychiatry Cord Blood Study — 2020
A landmark study published in JAMA Psychiatry used a novel biomarker approach — measuring actual acetaminophen concentrations in umbilical cord blood at birth — to assess prenatal exposure with greater precision than prior recall-based studies. Children in the highest tertile of cord-blood acetaminophen concentrations had a 2.86 times greater risk of ADHD and a 3.62 times greater risk of ASD compared to children with the lowest concentrations. This study was significant because it used objective biological measurements of exposure rather than maternal self-report, addressing a key methodological criticism of earlier studies. It became a cornerstone of plaintiffs' expert testimony in MDL-3043.
scientificNotable Verdicts & Settlements
MDL-3043 — No Final Verdicts; Federal Cases Dismissed August 2024
VerdictMDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation, S.D.N.Y., Judge Denise L. Cote) was dismissed in August 2024 after Judge Cote excluded all of plaintiffs' general causation expert witnesses under the Daubert standard. No bellwether trials were held and no verdicts were reached in the federal MDL before dismissal. The Second Circuit heard oral arguments on the appeal on November 17, 2025. This entry documents the procedural status — not a favorable outcome — so that claimants have accurate information about where the federal litigation stands.
Benchmark: Vioxx MDL Settlement — Comparable Pharmaceutical Mass Tort
SettlementThe Vioxx MDL (In re: Vioxx Products Liability Litigation, E.D. La.) resulted in a $4.85 billion global settlement between Merck and approximately 50,000 claimants following Vioxx's 2004 FDA withdrawal for cardiovascular risks. This is provided as a reference benchmark for pharmaceutical mass tort scale — not as a Tylenol-autism case outcome. Individual Vioxx claimant recoveries ranged from $0 (cases that did not qualify) to over $1 million for the most severe cardiovascular injury claims. A comparable resolution of the Tylenol-autism litigation — if the Second Circuit reverses and the MDL revives, or if state court cases reach settlement — would likely produce a structured global settlement rather than individual jury verdicts.
Benchmark: Camp Lejeune Water Contamination — Neurodevelopmental Harm Claims
SettlementThe Camp Lejeune Justice Act of 2022 authorized claims for individuals exposed to contaminated water at Camp Lejeune, including children who developed neurodevelopmental conditions as a result of in utero exposure to toxic chemicals. The Department of Justice has offered benchmark settlement values for qualifying conditions. This entry is provided as a reference for neurodevelopmental harm compensation in a government-authorized context — not as a direct Tylenol-autism comparison. The Camp Lejeune framework demonstrates that neurodevelopmental injury to children from prenatal toxic exposure is recognized as a legally compensable harm category with substantial settlement values.
Benchmark: SSRI-Birth Defect Litigation (Zoloft/Paxil MDL) — Pharmaceutical Prenatal Exposure
SettlementLitigation over SSRI antidepressants (Zoloft, Paxil) alleging prenatal exposure caused birth defects and neurodevelopmental harm provides an analogous precedent for acetaminophen-autism claims. GlaxoSmithKline paid $3 billion in 2012 to resolve criminal and civil claims related to Paxil, including off-label promotion for use during pregnancy. Individual prenatal SSRI exposure cases involving neurodevelopmental harm settled in the range of $100,000 to $500,000 depending on severity. These confidential outcomes inform the projected settlement ranges used in the Tylenol-autism litigation analysis. The SSRI precedent also demonstrates that pharmaceutical defendants will settle prenatal-harm cases once legal liability is established, even before trial verdicts.
California State Court — Acetaminophen-Autism Cases Active in Alameda County (No Verdict Yet)
VerdictAs of February 2026, California state court cases (Alameda County) alleging that prenatal acetaminophen exposure caused autism and ADHD are proceeding under the Kelly-Frye admissibility standard. No California verdict has been reached as of this writing. This entry tracks the California state court litigation as a live, active docket — unlike the dismissed federal MDL. An April 2025 trial date was scheduled in at least one California coordinated proceeding. The outcome of these California cases will be the most significant near-term data point for claimant valuation and overall litigation trajectory. We will update this entry as California proceedings advance in 2026.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Tylenol Autism Lawsuit Case Page